14 July 2022

Navitas Life Sciences, a provider of Clinical, Pharmacovigilance, and Regulatory solutions, today announced that it has been named a ‘Major Contender’ in the Everest Group’s Clinical Development Platforms Products PEAK Matrix® Assessment 2022.

The PEAK Matrix® assessment provides the analysis and insights that enterprises need to make critical selection decisions about service providers, locations, and products and solutions.

For this research report, Navitas Life Sciences is one of 22 global service providers to feature. The report looks at the vendor landscape of clinical development platforms and presents an in-depth analysis and insights into these platforms. Capabilities have been assessed and mapped using a composite index of distinct metrics related to a vendor’s capability and market impact.

The report acknowledges that the COVID-19 pandemic accelerated the adoption of digital technologies, data sciences, analytics, and automation tools, enabling remote services and preserving the continuity of care.

At Navitas Life Sciences we are proud to be driving better outcomes for drug development with clinical research that is data-driven, patient-centric, and ensures efficient trials to speed products to market. Motivated by the success of our clients, we work to accelerate access to better healthcare for people across the globe with our end-to-end services and solutions for life sciences.

For further information, or to read the Everest Group’s Clinical Development Platforms Products PEAK Matrix® Assessment 2022 please visit: https://www2.everestgrp.com/reportaction/EGR-2022-46-R-5266/Marketing